Idiopathic constipation
Drug research and approvals for idiopathic constipation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 5 studies of idiopathic constipation are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 5
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 5 recruiting on ClinicalTrials.gov ↗
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsNCT07382167 · Phase 3 · Ardelyx · starts Jan 13, 2026
- MowOot and Trans-anal Irrigation fOr coNstipationNCT06833684 · Not applicable · usMIMA S.L. · starts Jun 25, 2025
- Maralixibat in Patients With Cystic Fibrosis and ConstipationNCT06413368 · Phase 2 / Phase 3 · Children's Hospital Los Angeles · starts Apr 9, 2025
- A Study of Prucalopride in Breastfeeding Women With ConstipationNCT04838522 · Not reported · Takeda · starts Mar 2, 2022
- Safety and Efficacy of Fecal Microbiota TransplantationNCT04014413 · Not applicable · Chinese University of Hong Kong · starts Jul 15, 2019
Newest first; search them all in Canada trials
| Mar 7, 2014 | An open-label extension (OLE), long-term safety and tolerability study of plecanatide in patients with chronic idiopathic constipation (CIC)Plecanatide | Synergy Pharmaceuticals Inc | Ongoing |
| Mar 7, 2014 | A randomized, 12-week, double-blind, placebo-controlled study to assess the safety and efficacy of plecanatide (3.0 and 6.0 mg) in patients with chronic…Plecanatide | Synergy Pharmaceuticals Inc | Closed |
| Apr 30, 2013 | A multicenter, open-label, safety and tolerability extension trial of 5 mg and 10 mg elobixibat daily in the treatment of chronic idiopathic constipation.Elobixibat (FE999314) | Ferring Pharmaceuticals | Ongoing |
| Apr 30, 2013 | A double-blind, randomised, placebo-controlled, phase 3 trial in patients with chronic idiopathic constipation to demonstrate the efficacy and safety of…Elobixibat (FE999314) | Ferring Pharmaceuticals | Pending |
| Apr 30, 2013 | A double-blind, randomised, placebo-controlled, phase 3 trial in patients with chronic idiopathic constipation to demonstrate the efficacy and safety of…Elobixibat | Ferring Pharmaceuticals | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA